The U.S. is the largest pharmaceutical market by value and its drug spending has continued to outgrow the global market — and this is largely driven by biologics, which have seen a compound annual growth rate of 12%. But as these new and innovative therapeutics race towards commercialization, the industry is grappling with the challenges of their highly complex and specific manufacturing processes.
This eBook will explore:
An in-depth look at the reappearing of antibody-drug conjugates
What it will take to make precision medicine a reality
How computational and AI advancements can help solve process design inefficiencies
How reducing technology-addressable vaccine barriers affects coverage rates
